Metrics as of 10/16/2026, 07:12 PM (Berlin time), refresh in progress.
Freenome, Inc.
Freenome is an early cancer detection company developing blood-based screening tests to identify cancer in its earliest, most treatable stages. The company's proprietary multiomics discovery platform analyzes circulating cell-free DNA methylation patterns at single-base resolution alongside additional biomarkers to…
1D
-3.6%
1W
-24.9%
1M
-19.6%
6M
–
YTD
–
1Y
–
2Y
–
5Y
–
10Y
–
Next earnings date
02/12/2026 (in 46 days)
Volatility around earnings
Not enough history for an assessment
PRICE TARGET LOW
US$17.00
CONSENSUS
US$18.25
MEDIAN
US$17.50
PRICE TARGET HIGH
US$21.00
No current analyst ratings available.
FREE FLOAT
–
FLOAT SHARES
7,120,995
AVG. DAILY VOLUME (30D)
832,138
Elliott Aaron Matthew
Waksal Harlan
Freenome, Inc. is a company in the Healthcare sector, Medical - Diagnostics & Research industry, headquartered in United States.
The CEO is Aaron Elliott, the company employs around 378 people.
The IPO was on 21/07/2026; the stock trades on NASDAQ under the ticker FRNM.
The average price target is US$18.25, ranging from US$17.00 to US$21.00, with a median of US$17.50.
This is an external assessment, not a statement by Market Jury.
The next earnings date is 02/12/2026.
No, Freenome currently does not pay a dividend.
Comparable stocks include Thermo Fisher Scientific, Danaher, Natera, Agilent Technologies, IQVIA Holdings, Waters, Illumina and IDEXX Laboratories.
Clicking "Analyze stock" lets five strategies assess Freenome against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.